GNTA
Genenta Science SpA ADR
NASDAQ: GNTA · HEALTHCARE · BIOTECHNOLOGY
$0.71
-1.99% today
Updated 2026-04-29
Market cap
$16.71M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.39
Dividend yield
—
52W range
$1 – $6
Volume
0.1M
Genenta Science SpA ADR (GNTA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — |
| Cost of revenue | — | $1768.00 | $5096.00 | $5996.00 | $41705.00 | $46508.00 | $26973.00 |
| Gross profit | — | $-1768.00 | $-5096.00 | $-5996.00 | $-41705.00 | $-46508.00 | $-26973.00 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $3.65M | $4.36M | $3.53M | $5.21M | $6.36M | $5.03M | $2.59M |
| SG&A | $921520.00 | $901765.00 | $2.30M | $5.71M | $5.26M | $4.95M | $3.90M |
| Operating income | $-4.56M | $-5.20M | $-5.93M | $-10.79M | $-11.53M | $-10.20M | $-6.34M |
| Operating margin | — | — | — | — | — | — | — |
| EBITDA | $-4.56M | $-5.20M | $-5.92M | $-10.78M | $-11.48M | $-10.15M | $-6.32M |
| EBITDA margin | — | — | — | — | — | — | — |
| EBIT | $-4.62M | $-5.20M | $-5.93M | $-10.79M | $-11.53M | $-10.20M | $-6.34M |
| Interest expense | $9552.00 | $7754.00 | $11716.00 | $2.57M | — | — | $384212.00 |
| Income tax | $9552.00 | $13720.00 | $31373.00 | $-4.85M | $4.00 | — | — |
| Effective tax rate | -0.2% | -0.3% | -0.5% | 37.0% | -0.0% | 0.0% | 0.0% |
| Net income | $-4.53M | $-5.20M | $-5.76M | $-8.28M | $-11.44M | $-9.31M | $-6.27M |
| Net income growth (YoY) | — | -14.8% | -10.8% | -43.6% | -38.2% | +18.6% | +32.6% |
| Profit margin | — | — | — | — | — | — | — |